Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 31Carcinoma, Hepatocellular 30Neoplasms 19Carcinoma, Renal Cell 16Melanoma 10Carcinoma, Non-Small-Cell Lung 10Thyroid Neoplasms 9Endometrial Neoplasms 9Squamous Cell Carcinoma of Head and Neck 6Colorectal Neoplasms 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Liver Neoplasms 4Carcinoma, Transitional Cell 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Lymphoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma 3Biliary Tract Neoplasms 3Stomach Neoplasms 2Solid Tumors 2Osteosarcoma 2Lung Neoplasms 2Kidney Neoplasms 2Glioma 2Diabetes Mellitus, Insulin-Dependent, 12 2

Interventions

pembrolizumab 3napabucasin 3Bevacizumab 3entinostat 2Paclitaxel 2Ocoxin 2Leucovorin 2Irinotecan 2Immunotherapy 2Gemcitabine 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vorasidenib 1sipuleucel-T 1pralsetinib 1palbociclib 1luprolide acetate gel depot 1linifanib 1lenvatinib 1interferon gamma-1b 1ficlatuzumab 1durvalumab 1catumaxomab 1Vaccines 1VB6-845 fusion protein 1Taxes 1Sorafenib 1Pemetrexed 1Papillomavirus Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Glandular and Epithelial × lenvatinib × Clear all
NCT04008082 2022-03-08

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Eisai Inc.

Completed
412 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡